Nutra Pharma Corp. (NPHC.OB) Subsidiary Introduces Cost Effective Contract Research Services
Nutra Pharma Corp., a biotechnology company focused on developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), announced today that its wholly-owned drug discovery subsidiary, ReceptoPharm, has introduced a line of specialized contract research services targeted at the early-stage life science market. “As a clinical stage company specializing in biologics, we understand and have cleared many of the hurdles that face emerging biotech companies,” stated Dr. Paul Reid, CEO of ReceptoPharm. “This knowledge, combined with our qualified drug production facility, allows us to leverage our expertise and capabilities by extending them to small and start-up biotechnology companies looking for…